Ekso Bionics Holdings, Inc. (EKSO) Upgraded to “Buy” by Zacks Investment Research
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday. The firm presently has a $1.50 price target on the stock. Zacks Investment Research‘s price objective points to a potential upside of 30.43% from the company’s current price.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Ekso Bionics Holdings (NASDAQ:EKSO) traded down 6.50% during midday trading on Friday, hitting $1.15. The stock had a trading volume of 613,937 shares. The firm’s market capitalization is $29.66 million. The firm has a 50-day moving average price of $1.49 and a 200-day moving average price of $2.20. Ekso Bionics Holdings has a 1-year low of $0.99 and a 1-year high of $6.38.
COPYRIGHT VIOLATION NOTICE: “Ekso Bionics Holdings, Inc. (EKSO) Upgraded to “Buy” by Zacks Investment Research” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/15/ekso-bionics-holdings-inc-ekso-upgraded-to-buy-by-zacks-investment-research.html.
In related news, insider Russ Angold sold 221,746 shares of Ekso Bionics Holdings stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $1.55, for a total transaction of $343,706.30. Following the completion of the sale, the insider now owns 400,678 shares of the company’s stock, valued at $621,050.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have purchased 41,264 shares of company stock valued at $48,255 and have sold 259,352 shares valued at $399,373. 7.10% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Intellectus Partners LLC boosted its stake in Ekso Bionics Holdings by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares during the period. Vanguard Group Inc. boosted its stake in Ekso Bionics Holdings by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares during the period. National Planning Corp boosted its stake in Ekso Bionics Holdings by 116.2% during the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after buying an additional 126,000 shares during the period. Carl Domino Inc boosted its stake in Ekso Bionics Holdings by 74.7% during the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after buying an additional 35,088 shares during the period. Finally, Independence Advisors LLC bought a new stake in Ekso Bionics Holdings during the second quarter valued at $1,840,000. 6.04% of the stock is owned by institutional investors.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.